MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.
This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions, public technology transfer offices, biotech and biopharma customers with a fully integrated platform for antibody-based therapeutic development in the cancer and inflammation fields.
“We are pleased to be leading the way in antibody discovery with Berkeley Lights,” said Thierry Jean, Chief Executive Officer of MImAbs. “In our initial testing of the Beacon system, the results were more than we even thought possible. With its abilities to deliver against a range of targets that fail with traditional technologies, increase yields and diversity in the other cases and under timelines that are weeks and not months, the Beacon system is a clear competitive advantage for us. Our skills in immunisation and immunogen design, generation of screening tools such as high expression transfectants and downstream biology of monoclonal antibodies provide an ideal environment to take full advantage of the technology.”
Image credit: Gerd Altmann